Key facts
- This page summarizes Gisele Dion's Form 4 filing for Cytek Biosciences, Inc. (CTKB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2023, 18:36.
Gisele Dion - 14 Jun 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)
- Reporting relationship
- Director
- Issuer ticker
- CTKB
- Reported as of
- 14 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 18:36:57 UTC
- Prior SEC filing
- 06 Sep 2022
- Next SEC filing
- 05 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Valerie Barnett, Attorney-in-Fact for Gisele Dion
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gisele Dion filed Form 4 for Cytek Biosciences, Inc. (CTKB) on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 06 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTKB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +30,242
- Change %
- Price
- $0.000000
- Shares after
- 30,242
- Date
- 14 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,242
- Exercise price
- $8.38
* marks a reported price that did not pass the local price check.